Welcome to our dedicated page for Tonix Pharmaceut SEC filings (Ticker: TNXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tonix Pharmaceuticals Holding Corp. (TNXP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tonix is a Nevada corporation with common stock listed on The Nasdaq Capital Market under the symbol TNXP, and it uses Forms 8-K, 10-Q, 10-K and registration statements to report material events, financial results and securities offerings related to its commercial-stage biotechnology business.
For Tonix, current and prospective shareholders often focus on filings that explain the commercialization of its FDA-approved fibromyalgia medicine TONMYA, net product revenue from its acute migraine therapies Zembrace SymTouch and Tosymra, and the funding of its development portfolio in CNS disorders, immunology, rare disease and infectious disease. Form 8-K reports detail events such as FDA IND clearance for TNX-102 SL in major depressive disorder, licensing of TNX-4900 for chronic neuropathic pain, collaborations on TNX-1500 for kidney transplant rejection, and capital markets activities including amendments to sales agreements, registered direct offerings and share repurchase authorizations.
On this page, you can review quarterly reports (Form 10-Q) and annual reports (Form 10-K) for Tonix’s consolidated financial statements, risk factor discussions and descriptions of its product pipeline. Current reports on Form 8-K highlight specific milestones, while shelf registration statements and prospectus supplements describe the terms of equity offerings used to finance commercialization and clinical development. Insider transaction reports on Form 4, when available, help investors see how Tonix officers and directors are trading the company’s stock.
Stock Titan enhances these TNXP filings with AI-powered summaries that highlight key points, such as changes in cash runway, material agreements, clinical development plans and securities issuance. Real-time updates from EDGAR mean new Tonix filings appear promptly, while AI-generated explanations can save time for readers who want to understand the implications of lengthy documents like 10-Ks, 10-Qs or complex 8-K exhibits without reading every page.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 854,579 shares of Tonix Pharmaceuticals Holding Corp. common stock, representing 6.7% of the outstanding class as of 12/31/2025. BlackRock reports sole voting power over 845,544 shares and sole dispositive power over 854,579 shares, with no shared voting or dispositive power.
The filing explains that the position reflects securities beneficially owned, or deemed beneficially owned, by certain BlackRock business units, and excludes other disaggregated units. It also notes that various persons have the right to receive dividends or sale proceeds from these shares, but no single person has more than five percent of Tonix Pharmaceuticals Holding Corp.’s outstanding common stock. BlackRock certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Tonix Pharmaceuticals Holding Corp. licensed exclusive worldwide rights to TNX-4900, a small-molecule candidate for chronic neuropathic pain, from Rutgers University. TNX-4900 is a highly selective Sigma-1 receptor antagonist with nanomolar affinity (Ki = 7.5 nM) and more than hundred-fold selectivity over Sigma-2, intended as a non-opioid approach to treating neuropathic pain.
In preclinical models of diabetic and chemotherapy-induced neuropathic pain, TNX-4900 produced significant and durable reductions in pain behaviors after both acute and chronic dosing, without evidence of tolerance or motor impairment. The compound shows high blood-brain barrier penetration and oral bioavailability of approximately 28%. Tonix plans additional pharmacokinetic, formulation and safety studies to potentially support an Investigational New Drug application with the U.S. Food and Drug Administration.
Tonix Pharmaceuticals Holding Corp. reported that the U.S. FDA has cleared its Investigational New Drug application for TNX-102 SL 5.6 mg, enabling clinical development for treating major depressive disorder (MDD) in adults. The company plans a potentially pivotal Phase 2 HORIZON study, a 6-week, randomized, double-blind, placebo-controlled trial of TNX-102 SL as first-line monotherapy in about 360 adults across approximately 30 U.S. sites. The primary goal is to measure change in Montgomery-Asberg Depression Rating Scale-II scores at Week 6, with additional measures of overall clinical impression, anxiety, and sleep disturbance, and enrollment is planned to begin in mid-year 2026.
Tonix Pharmaceuticals (TNXP) is updating its at-the-market common stock offering program under its existing Sales Agreement with A.G.P./Alliance Global Partners. The company is now offering up to an aggregate of $400,000,000 of its common stock under this program.
Under the prior prospectus, Tonix had registered up to $150,000,000 and sold 3,882,223 shares of common stock for an aggregate purchase price of $103.1 million. Following this prospectus supplement dated November 21, 2025, Tonix may sell up to an additional $296.9 million of common stock under the Sales Agreement.
Tonix Pharmaceuticals Holding Corp. reported that on November 21, 2025 it amended its Sales Agreement with A.G.P./Alliance Global Partners. The amendment increases the maximum aggregate offering price of the company’s common shares that may be issued under the agreement from $150,000,000 to $400,000,000, giving Tonix a larger authorized capacity to sell stock through this program as needed over time. The company also filed a legal opinion on the validity of the shares issuable under the Sales Agreement as an exhibit.
Tonix Pharmaceuticals Holding Corp. reported that its Board of Directors approved an increase to its share repurchase program, authorizing the Company to buy back up to an additional $25.0 million of its outstanding common stock. This brings the total amount authorized for repurchases under the program to $35 million.
The decision signals that the Company is willing to allocate a meaningful amount of capital to repurchasing its own shares, which can reduce the number of shares in the market over time and may support shareholder value, depending on execution and future business needs.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported that its product TONMYA, a cyclobenzaprine HCl sublingual tablet, is now commercially available at pharmacies in the United States by prescription. This marks the move of TONMYA from development into the commercial marketplace, allowing eligible patients to obtain the drug through standard retail pharmacy channels.
The company released this information via a press release furnished as an exhibit, and emphasized that the disclosure includes forward-looking statements about its broader product development plans, regulatory timelines and market opportunities, which remain subject to various risks and uncertainties.
Tonix Pharmaceuticals (TNXP) reported Q3 2025 results. Product revenue was $3.29 million, up from $2.82 million a year ago. Operating loss was $33.07 million and net loss to common stockholders was $32.01 million, or $3.59 per share. Selling, general and administrative expenses were $25.70 million versus $7.71 million last year, and research and development was $9.29 million versus $9.11 million.
As of September 30, 2025, cash and cash equivalents were $190.06 million and total assets were $252.44 million. The company eliminated its term loan, reducing debt to zero from $4.67 million at December 31, 2024. Year‑to‑date, net cash provided by financing activities was $155.39 million, including $170.99 million of proceeds from sales of common stock and warrants.
Tonix received FDA approval for Tonmya in August 2025 and expects a U.S. launch before the end of November 2025. Management states current cash plus $34.7 million of Q4 2025 equity proceeds are expected to fund operations into the first quarter of 2027. Shares outstanding were 11,776,542 as of November 10, 2025.
Tonix Pharmaceuticals Holding Corp. filed a current report to disclose that it announced its operating results for the quarter ended September 30, 2025.
The company explains that these quarterly results are described in a press release dated November 10, 2025, which is attached as Exhibit 99.01 and incorporated by reference. The report is signed on behalf of the company by Chief Financial Officer Bradley Saenger.
Tonix Pharmaceuticals (TNXP) filed an 8-K with preliminary updates. The company believes its cash at September 30, 2025, plus $29.3 million of net proceeds from equity offerings in the fourth quarter of 2025, will cover planned operating and capital needs into the first quarter of 2027.
Management emphasized these are unaudited, preliminary estimates subject to completion of closing procedures and potential adjustments. The independent auditor has not audited, reviewed, or compiled this information. Tonix currently expects to file its Form 10-Q for the quarter ended September 30, 2025, on or about November 10, 2025.
The company also expects to commence the U.S. commercial launch of Tonmya for the treatment of fibromyalgia in adults by the end of November 2025.